Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplify Cybersecurity ETF (HACK) vs Viatris Inc (VTRS) Price & Performance

Amplify Cybersecurity ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Amplify Cybersecurity ETF vs Viatris Inc — how do they compare? Amplify Cybersecurity ETF trades at $130.76 (market cap $3.50B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 5.7× Amplify Cybersecurity ETF's market cap, and Viatris Inc pays a 2.75% dividend while Amplify Cybersecurity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 28 Days and Viatris Inc for 57 Days on average.

HACKVTRS
Market Cap
$3.50B$20.03B
Volume
341,17614,109,977
Sector
Sector/ThematicHealth
52-Week High
$130.76$18.27
52-Week Low
$70.69$9.74
Typical Hold Time
28 Days57 Days
Enterprise Value
—$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplify Cybersecurity ETF

HACK trades at $130.76, up 3.93% today and near its 52-week high, reflecting strong momentum amid bullish technical signals. The ETF benefits from rising cybersecurity demand driven by AI safety concerns and recent earnings beats from holdings like CrowdStrike. Technical indicators show a bullish trend with support at $124 and resistance at $126, while short interest has surged, indicating mixed sentiment.

Outlook remains positive due to sector tailwinds from AI-driven cyber threats, but risks include high valuation sensitivity and increased short interest. The ETF's diversified exposure to cybersecurity leaders offers growth potential, though investor caution is warranted given its proximity to record highs and competitive pressures.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HACK
100% Buy0% Sell
Avg holding period · 28 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Amplify Cybersecurity ETF

HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.

Read more on HACK →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →